Sierra Oncology Acquires Gilead’s Momelotinib to Treat Myelofibrosis for ~$198M

 Sierra Oncology Acquires Gilead’s Momelotinib to Treat Myelofibrosis for ~$198M

Sierra Oncology Acquires Gilead’s Momelotinib to Treat Myelofibrosis for ~$198M

Shots:
  •  Sierra will pay $3M upfront and ~$195M milestone payments to Gilead and additional royalties from mid-teen-to-high-twenties on net sales
  • Sierra will continue all currently ongoing clinical studies with Momelotinib following a transition period
  • Momelotinib (a JAK 1/2 and ACVR1 Inhibitor) is in Phase III, has being administered to ~1200 patients, since 2009, and is expected to get patent exclusivity in EU and U.S. till 2033 and 2035 respectively  

Click here to read full press release/ article | Ref: Sierraoncology | Image:  Sierra oncology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post